NRI

Albert David Ltd

Sector Pharmaceuticals
BSE 524075
NSE ALBERTDAVD
890.00
38.50 (4.52 %)
Buy
B
Sell
S
NSE BSE

Overview

Day Low

812.05

Day High

900.00

52 Week Low

812.05

52 Week High

1,753.95

All Time Low

263.00

All Time High

1,753.95

Open

852.95

Close

851.50

Volume

23,629

Mkt cap (Cr)

507.92

P/E ratio

12.57

P/B ratio

0.81%

Div yield

1.29%

6M return

-23.55%

1Y return

-36.64%

1D 1W 1M 3M 6M 1Yr 3Yr 5Yr 10Yr Max
Price PE Ratio
 

We appreciate your patience. Your content is on the way.

SWOT Analysis

  • S
  • W
  • O
  • T

Technical Analysis

Moving Averages

EMA SMA
 

We appreciate your patience. Your content is on the way.

890.00 4.52%

Current Price

  • Bullish Moving Averages
  • Bearish Moving Averages

Resistance and support

 

We appreciate your patience. Your content is on the way.

Company Financials

  • Profit and loss statement
  • Balance sheet
  • Quarterly Result
  • Ratio
 

We appreciate your patience. Your content is on the way.

Quick Results Snapshot

 

We appreciate your patience. Your content is on the way.

Shareholding Pattern

Summary

 

We appreciate your patience. Your content is on the way.

 

We appreciate your patience. Your content is on the way.

Historical Promoter Summary

 

We appreciate your patience. Your content is on the way.

Promoter Holding(%)

Historical FII Holdings

 

We appreciate your patience. Your content is on the way.

FII Holding(%)

Historical MF Holdings

 

We appreciate your patience. Your content is on the way.

MF Holding(%)

Stocks Comparison
Table Chart

 

We appreciate your patience. Your content is on the way.

Corporate Action

  • Announcement
  • Board Meeting
  • Dividend
  • Split
  • Rights
  • Events

Insider & Institutional Activity

  • Bulk Block Deals
  • Insider Trading & SAST
 

We appreciate your patience. Your content is on the way.

About Albert David Ltd

Stock PE (TTM)

12.57

Promoter Holding

62.13%

Book Value

723.7093

ROCE

26.86%

ROE

21.72%

Albert David Limited (ADL), a Unit of Kothari Group, was incorporated in 1938 at Calcutta. The Company belongs to a renowned industrial house of Kolkata, the "Kothari Group". The Company`s principal business is manufacturing and trading of Pharmaceutical Formulations, Infusion Solutions, Herbal Dosage Forms and Bulk Drugs by way of domestic sale or export. Apart from these, it manufactures disposable syringes and needles and a wide range of bulk drugs. It is recognised as a large IV fluid manufacturer, both in glass and polyethylene containers. ADL has entered into a technical collaboration with Morishita Pharmaceuticals, Japan, a subsidiary of Ajinomoto -- the world leader in amino acids -- to manufacture amino acid infusions, for which it came out with a rights issue in Aug.`87. It has also set up a new unit in Kalyani, West Bengal, to manufacture bulk drugs, which went on stream in 1990. Another rights issue in Mar.`90 augmented the long-term working capital. ADL has entered into technical collaboration with Pharma Plan, Germany, to supply machinery to manufacture 30 mln disposable syringes and 70 mln needles at Mandideep near Bhopal. ADL came up with a Rs 4.68-cr right issue to part finance the expansion of its capacity of IV fluids in plastic bottles (FFS technology) at Ghaziabad. During 1998-99, the company has developed some new products viz. Siozole Capsules and Ferrochelate-Z-Capsules with Iron & Zinc and folic acid in sustained released formulation. In 2002-03 the company has launched new products-INTECAR,NIMERIL-T,EVICT,ALROF-50. It is also planning to launch new products such as SIOOXY,ALAMIN FEZ,PANSURE. New products were launched such as - INTECAR Capsules, NIMERIL-T, EVICT, ALROF-50, ADLIN and SLOZIN during the year 2003; new products such as Alamin-FeZ and Pansure were introduced in 2004. SIOOXY (Anti-Oxidant with OMEGA-3 Fatty Acid) was launched in 2005, launched ALAMTN-Xtra, VERBET - the antivertigo drug and water for injection during year 2006; launched Antibiotic Azithromycin under brand `AZ3` and expanded its Vision Care range (launched Antiglaucoma products, Antiinfectives, Irrigating Solution and Steroidal combinations) in 2009; launched uterine tonic-Siocare and Laxative combination-Evict Fibre and has also expanded its Anti-inflammatory & Analgesic range with launch of Anaflam XP in 2010; launched Rabeprazole and its combination (Anti-Peptic Ulcerant range) and Montelukast and its combination (Anti Asthmatic range) in 2013; launched Alamin Liquid and Alamin RLD (L-Arginine Sachet) in 2014; launched Dhup Tab & Drop (Vit.D3), Inbalanse-Z (probiotic) and Evict-XF (Laxative) in 2015; launched Sioneuron M/PG capsules, Inbalanse-Z capsules and Breaze-Fx tablet in 2017. It introduced two products i.e., Evacure and C3H in the market during year 2021-22.

Albert David share price as on 18 Feb 2025 is Rs. 890. Over the past 6 months, the Albert David share price has decreased by 23.55% and in the last one year, it has decreased by 36.64%. The 52-week low for Albert David share price was Rs. 812.05 and 52-week high was Rs. 1753.95.

Read More
Registered Office  
Registrars  
Management  
Listing Info  

524075

ALBERTDAVD

INE155C01010

Aug

Albert David Ltd FAQs

You can buy Albert David Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Albert David Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Feb 17, 2025 03:50 PM the closing price of Albert David Ltd was Rs.890.00.

The latest PE ratio of Albert David Ltd as of Feb 17, 2025 03:50 PM is 12.57

The latest PB ratio of Albert David Ltd as of Feb 17, 2025 03:50 PM is 0.81

The 52-week high of Albert David Ltd share price is Rs. 1,753.95 while the 52-week low is Rs. 812.05

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Feb 17, 2025 03:50 PM, the market cap of Albert David Ltd stood at Rs. 507.92 Cr.

Market Outlook

View all
 

We appreciate your patience. Your content is on the way.